McKesson, CD&R Reportedly in Talks for $5B Option Care Health Deal

What's Happening McKesson Corporation and private equity firm Clayton, Dubilier & Rice (CD&R) are reportedly in talks to acquire Option Care Health in a deal valued around $5 billion, according to the Financial Times. Option Care Health is a major player in home and alternate-site infusion therapy — think IV medications and specialty treatments delivered outside traditional hospital settings.

Neither company has confirmed the talks publicly, and as with any early-stage M&A reporting, terms could shift or the deal could fall apart entirely. But the fact that McKesson — one of the largest pharmaceutical distributors in the country — is circling Option Care Health signals something bigger about where healthcare dollars are flowing.

Why McKesson Wants In McKesson has spent recent years diversifying beyond its traditional drug distribution business, pushing into specialty pharmacy, oncology, and biopharma services. Option Care Health fits that pattern. The home infusion market has grown steadily as insurers and health systems look for cheaper alternatives to hospital-based care, and infusion therapy for things like chemotherapy, antibiotics, and immunoglobulin treatments is a sticky, recurring revenue business.

Pairing with CD&R — a private equity firm with deep healthcare investment experience — suggests this could be structured as a joint buyout rather than a straight corporate acquisition, which would let McKesson gain exposure to the asset without taking on the full balance sheet risk alone.

What It Means for the Stock Option Care Health shares are likely to see volatility as this story develops. Deal talks at this stage typically trigger a premium bump in share price on speculation alone, even before anything is finalized. Investors watching MCK or OPCH should expect official statements, regulatory filings, or a denial in the coming days or weeks if talks are serious.

The Bigger Picture This isn't happening in a vacuum. Healthcare M&A has been heating up as companies try to control costs by consolidating specialty care delivery — moving treatment out of hospitals and into homes or clinics. If this deal happens, it would be one of the more notable moves in the home infusion space in recent years, and it could prompt competitors to make their own consolidation plays.